Payment overview · 2025
General Payments
$562.97
29 reported records · 7 companies
Healthcare provider profile · identity verified
Arthur J Craig, MD
Allopathic & Osteopathic Physicians|Internal Medicine · CINCINNATI, OH · NPI 1700862828
Verified facts
What the public records show
CMS Open Payments records show Arthur J Craig, MD received $562.97 in general payments during 2025 across 29 reported records.
AstraZeneca Pharmaceuticals LP accounted for 42.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Synthroid by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $238.52 | 42.4% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $159.45 | 28.3% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $83.44 | 14.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $29.75 | 5.3% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.99 | 3.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.87 | 3.2% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.95 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $562.97 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $159.45 | 11 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $140.06 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $138.81 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $99.71 | 7 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $83.44 | 4 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $83.44 | 4 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $29.75 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.99 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.52 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
34 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 320 | 119 |
| Amlodipine Besylate | Amlodipine Besylate | 301 | 103 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 278 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 78 |
| Gabapentin | Gabapentin | 251 | 58 |
| Omeprazole | Omeprazole | 246 | 88 |
| Losartan Potassium | Losartan Potassium | 241 | 87 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 183 | 29 |
| Potassium Chloride | Potassium Chloride | 171 | 66 |
| Alprazolam | Alprazolam | 150 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 30 |
| Metformin Hcl Er | Metformin Hcl | 141 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 55 |
| Allopurinol | Allopurinol | 138 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 138 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 134 | 42 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 48 |
| Lisinopril | Lisinopril | 131 | 53 |
| Eliquis | Apixaban | 127 | 26 |
| Alendronate Sodium | Alendronate Sodium | 126 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 122 | 44 |
| Lorazepam | Lorazepam | 120 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 119 | 48 |
| Jardiance | Empagliflozin | 118 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 43 |
| Trazodone Hcl | Trazodone Hcl | 104 | 39 |
| Ezetimibe | Ezetimibe | 99 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 99 | 42 |
| Methylprednisolone | Methylprednisolone | 96 | 71 |
| Ozempic | Semaglutide | 89 | 17 |
| Metformin Hcl | Metformin Hcl | 85 | 37 |
| Diazepam | Diazepam | 84 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 81 | 46 |
| Furosemide | Furosemide | 81 | 39 |
| Azithromycin | Azithromycin | 79 | 62 |
| Tramadol Hcl | Tramadol Hcl | 73 | 16 |
| Atenolol | Atenolol | 68 | 19 |
| Famotidine | Famotidine | 68 | 22 |
| Pregabalin | Pregabalin | 68 | 13 |
| Spironolactone | Spironolactone | 65 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 22 |
| Pioglitazone Hcl | Pioglitazone Hcl | 62 | 23 |
| Meloxicam | Meloxicam | 61 | 27 |
| Sertraline Hcl | Sertraline Hcl | 61 | 21 |
| Trulicity | Dulaglutide | 61 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 55 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 53 | 21 |
| Carvedilol | Carvedilol | 52 | 14 |
| Clonazepam | Clonazepam | 51 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 19 |
| Torsemide | Torsemide | 51 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 15 |
| Valsartan | Valsartan | 44 | 15 |
| Celecoxib | Celecoxib | 43 | suppressed |
| Prednisone | Prednisone | 43 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 42 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 16 |
| Testosterone | Testosterone | 42 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | 12 |
| Glimepiride | Glimepiride | 40 | 16 |
| Bupropion Xl | Bupropion Hcl | 39 | 13 |
| Cephalexin | Cephalexin | 39 | 30 |
| Oxycodone Hcl | Oxycodone Hcl | 39 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 37 | 15 |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 29 |
| Doxepin Hcl | Doxepin Hcl | 36 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 28 |
| Modafinil | Modafinil | 35 | suppressed |
| Simvastatin | Simvastatin | 35 | 15 |
| Synthroid | Levothyroxine Sodium | 34 | 11 |
| Azelastine Hcl | Azelastine Hcl | 33 | 16 |
| Temazepam | Temazepam | 33 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 23 |
| Donepezil Hcl | Donepezil Hcl | 31 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 14 |
| Naproxen | Naproxen | 31 | 11 |
| Ondansetron Odt | Ondansetron | 30 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 29 | 27 |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | 13 |
| Divalproex Sodium | Divalproex Sodium | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 28 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 26 | suppressed |
| Creon | Lipase/Protease/Amylase | 24 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 14 |
| Irbesartan | Irbesartan | 24 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 24 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 24 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Folic Acid | Folic Acid | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 11 |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 12 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 14 |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 15 | suppressed |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Eplerenone | Eplerenone | 13 | suppressed |
| Glipizide Er | Glipizide | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Klor-Con M10 | Potassium Chloride | 12 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fenofibrate | Fenofibrate | 11 | suppressed |
| Galantamine Er | Galantamine Hbr | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Novolog | Insulin Aspart | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $562.97 · 29 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, FARXIGA, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, UBRELVY, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error